Lucio Gnessi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1541231/publications.pdf Version: 2024-02-01

		71102	102487
128	5,288	41	66
papers	citations	h-index	g-index
132	132	132	8842
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Female infertility in the era of obesity: The clash of two pandemics or inevitable consequence?. Clinical Endocrinology, 2023, 98, 141-152.	2.4	8
2	Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVIDâ€19 mRNA vaccine. Diabetes/Metabolism Research and Reviews, 2022, 38, e3465.	4.0	203
3	Rapid Weight Loss, Central Obesity Improvement and Blood Glucose Reduction Are Associated with a Stronger Adaptive Immune Response Following COVID-19 mRNA Vaccine. Vaccines, 2022, 10, 79.	4.4	27
4	Application of a Machine Learning Technology in the Definition of Metabolically Healthy and Unhealthy Status: A Retrospective Study of 2567 Subjects Suffering from Obesity with or without Metabolic Syndrome. Nutrients, 2022, 14, 373.	4.1	8
5	Circulating SIRT1 and Sclerostin Correlates with Bone Status in Young Women with Different Degrees of Adiposity. Nutrients, 2022, 14, 983.	4.1	4
6	The Influence of Ketone Bodies on Circadian Processes Regarding Appetite, Sleep and Hormone Release: A Systematic Review of the Literature. Nutrients, 2022, 14, 1410.	4.1	14
7	VLCKD in Combination with Physical Exercise Preserves Skeletal Muscle Mass in Sarcopenic Obesity after Severe COVID-19 Disease: A Case Report. Healthcare (Switzerland), 2022, 10, 573.	2.0	5
8	Sex difference in the safety and efficacy of bariatric procedures: a systematic review and meta-analysis. Surgery for Obesity and Related Diseases, 2022, 18, 983-996.	1.2	14
9	Whey Protein, L-Leucine and Vitamin D Supplementation for Preserving Lean Mass during a Low-Calorie Diet in Sarcopenic Obese Women. Nutrients, 2022, 14, 1884.	4.1	8
10	Updating obesity management strategies: an audit of Italian specialists. Eating and Weight Disorders, 2022, 27, 2653-2663.	2.5	1
11	Obesity and Psychological Factors Associated with Weight Loss after Bariatric Surgery: A Longitudinal Study. Nutrients, 2022, 14, 2690.	4.1	5
12	Obesity treatment within the Italian national healthcare system tertiary care centers: what can we learn?. Eating and Weight Disorders, 2021, 26, 771-778.	2.5	32
13	Ketogenic Diet as a Preventive and Supportive Care for COVID-19 Patients. Nutrients, 2021, 13, 1004.	4.1	27
14	L-Leucine Supplementation for Preserving Lean Mass During Low Calorie Diet in Sarcopenic Obese Women: A Pilot Study. Journal of the Endocrine Society, 2021, 5, A19-A19.	0.2	0
15	Very Low-Calorie Ketogenic Diets to Treat Patients With Obesity and Chronic Kidney Disease. , 2021, 31, 340-341.		6
16	Chronobiology and Metabolism: Is Ketogenic Diet Able to Influence Circadian Rhythm?. Frontiers in Neuroscience, 2021, 15, 756970.	2.8	9
17	Bone density and genomic analysis unfold cold adaptation mechanisms of ancient inhabitants of Tierra del Fuego. Scientific Reports, 2021, 11, 23290.	3.3	1
18	Ketogenic Diet for Obese COVID-19 Patients: Is Respiratory Disease a Contraindication? A Narrative Review of the Literature on Ketogenic Diet and Respiratory Function. Frontiers in Nutrition, 2021, 8, 771047.	3.7	11

#	Article	IF	CITATIONS
19	Is obesity the missing link between COVID-19 severity and air pollution?. Environmental Pollution, 2020, 266, 115327.	7.5	9
20	Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study. Nutrients, 2020, 12, 2141.	4.1	39
21	Blood SIRT1 Shows a Coherent Association with Leptin and Adiponectin in Relation to the Degree and Distribution of Adiposity: A Study in Obesity, Normal Weight and Anorexia Nervosa. Nutrients, 2020, 12, 3506.	4.1	15
22	Weight Gain in a Sample of Patients Affected by Overweight/Obesity with and without a Psychiatric Diagnosis during the Covid-19 Lockdown. Nutrients, 2020, 12, 3525.	4.1	50
23	Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19. Metabolism: Clinical and Experimental, 2020, 111, 154319.	3.4	159
24	ls Growth Hormone Insufficiency the Missing Link Between Obesity, Male Gender, Age, and COVIDâ€19 Severity?. Obesity, 2020, 28, 2038-2039.	3.0	22
25	Current Evidence to Propose Different Food Supplements for Weight Loss: A Comprehensive Review. Nutrients, 2020, 12, 2873.	4.1	43
26	Nickel Sensitivity Is Associated with GH-IGF1 Axis Impairment and Pituitary Abnormalities on MRI in Overweight and Obese Subjects. International Journal of Molecular Sciences, 2020, 21, 9733.	4.1	10
27	Very-Low-Calorie Ketogenic Diets With Whey, Vegetable, or Animal Protein in Patients With Obesity: A Randomized Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2939-2949.	3.6	81
28	Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: A comprehensive review of the literature. Obesity Reviews, 2020, 21, e13024.	6.5	131
29	Scientific evidence underlying contraindications to the ketogenic diet: An update. Obesity Reviews, 2020, 21, e13053.	6.5	63
30	Very Low-Calorie Ketogenic Diet: A Safe and Effective Tool for Weight Loss in Patients with Obesity and Mild Kidney Failure. Nutrients, 2020, 12, 333.	4.1	113
31	Letter to the Editor: "Our Response to COVID-19 as Endocrinologists and Diabetologists― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2665-e2666.	3.6	2
32	Obesity and <scp>SARSâ€CoV</scp> â€2: A population to safeguard. Diabetes/Metabolism Research and Reviews, 2020, 36, e3325.	4.0	84
33	Case Report: Pituitary Morphology and Function Are Preserved in Female Patients With Idiopathic Intracranial Hypertension Under Pharmacological Treatment. Frontiers in Endocrinology, 2020, 11, 613054.	3.5	3
34	Application of recursive partitioning method (RPM) to select the multi-frequency bioimpedance analysis (MF-BIA) raw parameters predicting appendicular skeletal muscle mass index (SMI). Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 877.	2.6	0
35	The decline in muscle strength and muscle quality in relation to metabolic derangements in adult women with obesity. Clinical Nutrition, 2019, 38, 2430-2435.	5.0	36
36	A Randomized, Doubleâ€Blind, Placeboâ€Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity, 2019, 27, 205-216.	3.0	102

#	Article	IF	CITATIONS
37	Deregulation of the growth hormone/insulin-like growth factor-1 axis in adults with cystic fibrosis. Journal of Endocrinological Investigation, 2018, 41, 591-596.	3.3	8
38	Overweight and obese patients with nickel allergy have a worse metabolic profile compared to weight matched non-allergic individuals. PLoS ONE, 2018, 13, e0202683.	2.5	30
39	Mangosteen Extract Shows a Potent Insulin Sensitizing Effect in Obese Female Patients: A Prospective Randomized Controlled Pilot Study. Nutrients, 2018, 10, 586.	4.1	42
40	Testicular histopathology, semen analysis and FSH, predictive value of sperm retrieval: supportive counseling in case of reoperation after testicular sperm extraction (TESE). BMC Urology, 2018, 18, 63.	1.4	37
41	Inverse Association of Circulating SIRT1 and Adiposity: A Study on Underweight, Normal Weight, and Obese Patients. Frontiers in Endocrinology, 2018, 9, 449.	3.5	27
42	Androgens and Hypertension in Men and Women: a Unifying View. Current Hypertension Reports, 2017, 19, 44.	3.5	32
43	Natural antioxidant ice cream acutely reduces oxidative stress and improves vascular function and physical performance in healthy individuals. Nutrition, 2017, 33, 225-233.	2.4	31
44	An Exploratory Study on the Influence of Psychopathological Risk and Impulsivity on BMI and Perceived Quality of Life in Obese Patients. Nutrients, 2017, 9, 431.	4.1	12
45	Disability, Physical Inactivity, and Impaired Health-Related Quality of Life Are Not Different in Metabolically Healthy vs. Unhealthy Obese Subjects. Nutrients, 2016, 8, 759.	4.1	24
46	Circulating SIRT1 inversely correlates with epicardial fat thickness in patients with obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1033-1038.	2.6	21
47	Reduced sleep duration affects body composition, dietary intake and quality of life in obese subjects. Eating and Weight Disorders, 2016, 21, 501-505.	2.5	68
48	Attenuated IGF-1 predicts all-cause and cardiovascular mortality in a Black population: A five-year prospective study. European Journal of Preventive Cardiology, 2016, 23, 1690-1699.	1.8	19
49	Sarcopenic obesity and metabolic syndrome in adult Caucasian subjects. Journal of Nutrition, Health and Aging, 2016, 20, 958-963.	3.3	54
50	Assessment of trabecular bone score (TBS) in overweight/obese men: effect of metabolic and anthropometric factors. Endocrine, 2016, 54, 342-347.	2.3	45
51	Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients. Obesity Surgery, 2016, 26, 1215-1220.	2.1	36
52	Fatty Liver Index Associates with Relative Sarcopenia and GH/ IGF- 1 Status in Obese Subjects. PLoS ONE, 2016, 11, e0145811.	2.5	40
53	Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterology, 2015, 15, 153.	2.0	40
54	Adenovirus 36 and Obesity: An Overview. Viruses, 2015, 7, 3719-3740.	3.3	51

#	Article	IF	CITATIONS
55	Integrated Haematological Profiles of Redox <i>Status</i> , Lipid, and Inflammatory Protein Biomarkers in Benign Obesity and Unhealthy Obesity with Metabolic Syndrome. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-14.	4.0	22
56	Ovarian Function and Obesity: PCOS, Menopause. , 2015, , 73-82.		2
57	Severe growth hormone deficiency and empty sella in obesity: a cross-sectional study. Endocrine, 2015, 49, 503-511.	2.3	19
58	Safety and efficacy of a multiphase dietetic protocol with meal replacements including a step with very low calorie diet. Endocrine, 2015, 48, 863-870.	2.3	43
59	Adenovirus 36 DNA in human adipose tissue. International Journal of Obesity, 2015, 39, 1761-1764.	3.4	18
60	Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine, 2015, 49, 711-716.	2.3	101
61	Obesity treatment: results after 4Âyears of a Nutritional and Psycho-Physical Rehabilitation Program in an outpatient setting. Eating and Weight Disorders, 2014, 19, 249-260.	2.5	20
62	Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. Endocrine-Related Cancer, 2014, 21, 797-811.	3.1	28
63	Effects of Ultraviolet Radiation on FRTL-5 Cell Growth and Thyroid-Specific Gene Expression. Astrobiology, 2013, 13, 536-542.	3.0	4
64	Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology?. BMC Clinical Pathology, 2013, 13, 7.	1.8	39
65	Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy Leukemia Research Reports, 2013, 2, 58-60.	0.4	3
66	Association of epicardial fat thickness with the severity of obstructive sleep apnea in obese patients. International Journal of Cardiology, 2013, 167, 2244-2249.	1.7	52
67	Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica, 2013, 98, e25-e27.	3.5	49
68	Sella Turcica Atypical Teratoid/Rhabdoid Tumor Complicated with Lung Metastasis in an Adult Female. Clinical Medicine Insights: Case Reports, 2013, 6, CCRep.S12834.	0.7	34
69	Prevalence, Mass, and Glucose-Uptake Activity of 18F-FDG-Detected Brown Adipose Tissue in Humans Living in a Temperate Zone of Italy. PLoS ONE, 2013, 8, e63391.	2.5	55
70	Obesity and Metabolic Comorbidities: Environmental Diseases?. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-9.	4.0	51
71	Hypogonadism in a Patient with Two Novel Mutations of the Luteinizing Hormone Î ² -Subunit Gene Expressed in a Compound Heterozygous Form. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3031-3038.	3.6	38
72	Virilizing Leydig-Sertoli Cell Ovarian Tumor Associated with Endometrioid Carcinoma of the Endometrium in a Postmenopausal Patient: Case Report and General Considerations. Clinical Medicine Insights: Case Reports, 2012, 5, CCRep.S10555.	0.7	6

#	Article	IF	CITATIONS
73	In papillary thyroid carcinoma <scp>BRAF</scp> ^{V600E} is associated with increased expression of the urokinase plasminogen activator â€"and its cognate receptor, but not with diseaseâ€free interval. Clinical Endocrinology, 2012, 77, 780-786.	2.4	38
74	Relationships between Body Fat Distribution, Epicardial Fat and Obstructive Sleep Apnea in Obese Patients with and without Metabolic Syndrome. PLoS ONE, 2012, 7, e47059.	2.5	58
75	Obstructive sleep apnea and bone mineral density in obese patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2012, 5, 395.	2.4	29
76	Differential effects of the glycolysis inhibitor 2â€deoxyâ€ <scp>D</scp> â€glucose on the activity of proâ€apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. International Journal of Cancer, 2012, 131, E337-47.	5.1	61
77	Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertility and Sterility, 2011, 95, 1120.e15-1120.e17.	1.0	38
78	Reversible hair depigmentation in a patient treated with imatinib. Leukemia Research, 2011, 35, e64-e66.	0.8	19
79	High Expression of the Urokinase Plasminogen Activator and Its Cognate Receptor Associates with Advanced Stages and Reduced Disease-Free Interval in Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 504-508.	3.6	43
80	Determinants of microvascular damage recovery after acute myocardial infarction: results from the acute myocardial infarction contrast imaging (AMICI) multi-centre study. European Journal of Echocardiography, 2011, 12, 306-312.	2.3	20
81	Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leukemia Research, 2010, 34, e5-e7.	0.8	14
82	Role of Platelet-Derived Growth Factors in the Testis. Endocrine Reviews, 2010, 31, 916-939.	20.1	67
83	Corrigendum to "Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells― [FEBS Lett. 581 (2007) 5897-5903]. FEBS Letters, 2008, 582, 398-398.	2.8	0
84	Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet, The, 2008, 372, 111-112.	13.7	68
85	Platelet-Derived Growth Factor Receptor β-Subtype Regulates Proliferation and Migration of Gonocytes. Endocrinology, 2008, 149, 6226-6235.	2.8	69
86	Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment. Endocrine-Related Cancer, 2007, 14, 61-72.	3.1	17
87	Cadmium induces mitogenic signaling in breast cancer cell by an ERα-dependent mechanism. Molecular and Cellular Endocrinology, 2007, 264, 102-108.	3.2	168
88	lmatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. FEBS Letters, 2007, 581, 5897-5903.	2.8	35
89	Bone Metabolism and Endocrine Function in Children with Chronic Myeloid Leukemia (CML) Treated with Imatinib during Puberty Blood, 2007, 110, 2942-2942.	1.4	0
90	Expression and Cellular Localization of Follicle-Stimulating Hormone Receptor in Normal Human Prostate, Benign Prostatic Hyperplasia and Prostate Cancer. Journal of Urology, 2006, 175, 2072-2077.	0.4	70

#	Article	IF	CITATIONS
91	PAC1-Rnull isoform expression in human prostate cancer tissue. Prostate, 2006, 66, 514-521.	2.3	7
92	PACAP and Type I PACAP Receptors in Human Prostate Cancer Tissue. Annals of the New York Academy of Sciences, 2006, 1070, 440-449.	3.8	9
93	Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for <i>In vitro</i> and <i>In vivo</i> Activity. Cancer Research, 2005, 65, 1897-1903.	0.9	39
94	Expression of Platelet-Derived Growth Factor (PDGF) in the Epididymis and Analysis of the Epididymal Development in PDGF-A, PDGF-B, and PDGF Receptor β Deficient Mice. Biology of Reproduction, 2004, 70, 168-177.	2.7	27
95	Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet, The, 2003, 361, 1954-1956.	13.7	88
96	Ontogenesis of Leptin Receptor in Rat Leydig Cells1. Biology of Reproduction, 2003, 68, 1199-1207.	2.7	63
97	Expression of Platelet-Derived Growth Factor-A (PDGF-A), PDGF-B, and PDGF Receptor-α and -β during Human Testicular Development and Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2310-2319.	3.6	91
98	PDGF and the testis. Trends in Endocrinology and Metabolism, 2002, 13, 11-17.	7.1	46
99	Expression of Platelet-Derived Growth Factor-A (PDGF-A), PDGF-B, and PDGF Receptor-Â and -Â during Human Testicular Development and Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2310-2319.	3.6	78
100	Platelet-derived growth factor (PDGF) and PDGF receptors in rat corpus cavernosum: changes in expression after transient in vivo hypoxia. Journal of Endocrinology, 2001, 170, 395-402.	2.6	31
101	Fas and Fas Ligand Expression in Fetal and Adult Human Testis with Normal or Deranged Spermatogenesis. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2692-2700.	3.6	90
102	Leydig Cell Loss and Spermatogenic Arrest in Platelet-Derived Growth Factor (Pdgf)-a–Deficient Mice. Journal of Cell Biology, 2000, 149, 1019-1026.	5.2	210
103	Gonadal Peptides as Mediators of Development and Functional Control of the Testis: An Integrated System with Hormones and Local Environment*. Endocrine Reviews, 1997, 18, 541-609.	20.1	239
104	Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action Journal of Cell Biology, 1995, 131, 1105-1121.	5.2	81
105	Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone, 1995, 17, 383-390.	2.9	131
106	Immunohistochemical localization of growth hormone-releasing hormone in human gonads. Journal of Endocrinological Investigation, 1990, 13, 301-305.	3.3	39
107	IDENTIFICATION OF IMMUNOREACTIVE GASTRIN-RELEASING PEPTIDE RELATED SUBSTANCES IN ADULT RAT LEYDIG CELLS. Endocrinology, 1989, 124, 558-560.	2.8	15
108	Increased plasma beta-endorphin levels in hereditary angioedema. Immunopharmacology, 1989, 18, 89-96.	2.0	9

#	Article	IF	CITATIONS
109	Gastrin-releasing peptide-like immunoreactivity in porcine follicular fluid and ovary. Molecular and Cellular Endocrinology, 1989, 66, 115-118.	3.2	4
110	Neuroendocrine control of male reproductive function. The opioid system as a model of control at multiple sites. The Journal of Steroid Biochemistry, 1989, 32, 145-150.	1.1	77
111	Endorphins in male impotence: Evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology, 1989, 14, 103-111.	2.7	81
112	Isolation of a human seminal plasma peptide with bombesin-like activity. Fertility and Sterility, 1989, 51, 1034-1039.	1.0	12
113	Low Serum Bioactive Luteinizing Hormone In Nonorganic Male Impotence: Possible Relationship with Altered Conadotropin-Releasing Hormone Pulsatility. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 867-875.	3.6	36
114	Identification of Calcitonin Receptors in Human Spermatozoa. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 742-746.	3.6	37
115	Evidence for the Presence of Specific Receptors for NFormyl Chemotactic Peptides on Human Spermatozoa. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 841-846.	3.6	17
116	HUMAN SEMEN INHIBITS T ROSETTE FORMATION THROUGH AN OPIATE MEDIATED MECHANISM. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 807-809.	3.6	19
117	Naloxone increases bioactive LH in man: evidence for selective release of early LH pool. Journal of Endocrinological Investigation, 1985, 8, 513-517.	3.3	5
118	Calcitonin inhibits the phosphorylation of various proteins in rat brain synaptic membranes. Biochemical and Biophysical Research Communications, 1985, 130, 669-676.	2.1	9
119	Demonstration of receptor-mediated chemotaxis by human spermatozoa. Experimental Cell Research, 1985, 161, 219-230.	2.6	41
120	Naloxone Fails to Increase LH Levels in Clomiphene Treated Men. Hormone and Metabolic Research, 1984, 16, 140-141.	1.5	5
121	LACK OF ENDOGENOUS OPIOID INHIBITORY TONE ON LH SECRETION IN EARLY PUBERTY. Clinical Endocrinology, 1984, 20, 299-305.	2.4	64
122	Evidence for an inhibitory role of β-endorphin and other opioids on human total T rosette formation. Experientia, 1984, 40, 738-739.	1.2	35
123	Salmon calcitonin inhibits human sperm motility in vitro. Biochemical and Biophysical Research Communications, 1984, 125, 199-204.	2.1	21
124	Beta-endorphin, Met-enkephalin, and Calcitonin in Human Semen: Evidence for a Possible Role in Human Sperm Motility. Annals of the New York Academy of Sciences, 1984, 438, 365-370.	3.8	49
125	In vitro interaction between calcitonin and calmodulin. Biochemical and Biophysical Research Communications, 1984, 118, 648-654.	2.1	11
126	NALOXONE INHIBITS EXERCISEâ€iNDUCED RELEASE OF PRL AND GH IN ATHLETES. Clinical Endocrinology, 1983, 18, 135-138.	2.4	87

#	Article	IF	CITATIONS
127	Pyridoxine (B6) Suppresses the Rise in Prolactin and Increases the Rise in Growth Hormone Induced by Exercise. New England Journal of Medicine, 1982, 307, 444-445.	27.0	9
128	SUBARACHNOID CALCITONIN FOR INTOLERABLE PAIN. Lancet, The, 1982, 320, 831.	13.7	10